CEO
ANGANY
The startup develops allergy immunotherapy using enveloped bioparticles that mimic natural proteins to redirect the immune response, promoting tolerance instead of allergic reactions. This approach aims to provide long-term relief for individuals suffering from allergies by enhancing their immune system's ability to manage allergens.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$320KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops allergy immunotherapy using enveloped bioparticles that mimic natural proteins to redirect the immune response, promoting tolerance instead of allergic reactions. This approach aims to provide long-term relief for individuals suffering from allergies by enhancing their immune system's ability to manage allergens.